4//SEC Filing
Wheadon David E. 4
Accession 0000899243-22-034069
CIK 0001340652other
Filed
Oct 23, 8:00 PM ET
Accepted
Oct 24, 6:58 PM ET
Size
6.7 KB
Accession
0000899243-22-034069
Insider Transaction Report
Form 4
Wheadon David E.
Director
Transactions
- Disposition to Issuer
Restricted Stock Unit
2022-10-20−22,274→ 0 total→ Common Stock (22,274 underlying)
Footnotes (2)
- [F1]Reflects the disposition of securities pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 3, 2022, among Amgen Inc. ("Parent"), Carnation Merger Sub, Inc. ("Merger Sub") and ChemoCentryx, Inc. (the "Company"), pursuant to which, on October 20, 2022, Merger Sub merged with and into the Company, with the Company surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), each restricted stock unit of the Company held by the Reporting Person that was outstanding immediately prior to the Effective Time and that was (A) granted prior to August 3, 2022 or granted after August 3, 2022 and specified in the disclosure schedules delivered by the Company to Parent in connection with the Merger Agreement and/or (B) granted to a non-employee member of the board of directors of the Company became fully vested and was cancelled and converted into the right to receive an amount in cash,
- [F2](Continued from Footnote 1) less applicable withholding taxes and without interest, equal to (x) the total number of shares of common stock, par value $0.001 per share, of the Company underlying such restricted stock unit multiplied by (y) $52.00. The restricted stock units did not have an expiration date.
Documents
Issuer
ChemoCentryx, Inc.
CIK 0001340652
Entity typeother
Related Parties
1- filerCIK 0001789507
Filing Metadata
- Form type
- 4
- Filed
- Oct 23, 8:00 PM ET
- Accepted
- Oct 24, 6:58 PM ET
- Size
- 6.7 KB